Ardelyx (ARDX) Cash & Current Investments (2013 - 2026)
Ardelyx (ARDX) posted Cash & Current Investments of $238.1 million for Q1 2026, down 10.06% on a QoQ basis from $264.7 million in Q4 2025, and up 11.27% year-over-year from $214.0 million in Q1 2025.
Ardelyx (ARDX) Cash & Current Investments (2013 - 2026) Analysis & Trends
Ardelyx's Cash & Current Investments history runs 14 years deep, the most recent figure standing at $238.1 million for Q1 2026.
- Quarterly Cash & Current Investments rose 11.27% year-over-year to $238.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $238.1 million (up 11.27% YoY) and the FY2025 annual result came in at $264.7 million, up 5.83% from the prior year.
- Cash & Current Investments was $238.1 million for Q1 2026 at Ardelyx, down from $264.7 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $264.7 million in Q4 2025 and bottomed at $81.0 million in Q2 2022.
- A 5-year average of $177.6 million and a median of $186.0 million in 2024 frame the typical range for Cash & Current Investments.
- Annual changes were most pronounced in 2022 — Cash & Current Investments tumbled 52.85% — and 2023, when it soared 82.16%.
- Ardelyx's Cash & Current Investments stood at $123.9 million in 2022, then jumped by 48.74% to $184.3 million in 2023, then soared by 35.7% to $250.1 million in 2024, then increased by 5.83% to $264.7 million in 2025, then dropped by 10.06% to $238.1 million in 2026.
- Business Quant data shows ARDX's Cash & Current Investments at $238.1 million in Q1 2026, $264.7 million in Q4 2025, and $242.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,719.23 Bn | 65,718.94 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.85 Bn | 467.06 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 122.29 Bn | 115.04 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.28 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.47 Bn | 959.66 Mn | 3.01 Bn |
| 10 | Ardelyx | 1.26 Bn | 1.02 Bn | 89.66 Mn | 238.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 238.07 Mn |
| Dec 31, 2025 | 264.69 Mn |
| Sep 30, 2025 | 242.71 Mn |
| Jun 30, 2025 | 238.45 Mn |
| Mar 31, 2025 | 213.95 Mn |
| Dec 31, 2024 | 250.10 Mn |
| Sep 30, 2024 | 190.40 Mn |
| Jun 30, 2024 | 185.96 Mn |
| Mar 31, 2024 | 202.58 Mn |
| Dec 31, 2023 | 184.30 Mn |
| Sep 30, 2023 | 165.08 Mn |
| Jun 30, 2023 | 127.58 Mn |
| Mar 31, 2023 | 130.37 Mn |
| Dec 31, 2022 | 123.91 Mn |
| Sep 30, 2022 | 90.62 Mn |
| Jun 30, 2022 | 81.01 Mn |
| Mar 31, 2022 | 89.70 Mn |
| Dec 31, 2021 | 116.69 Mn |
| Sep 30, 2021 | 141.65 Mn |
| Jun 30, 2021 | 171.81 Mn |